Access to Soliris®
Physicians who care for patients with rare diseases need to be able to use innovative,
safe and effective new therapies to treat their patients. Alexion is committed to
the objective that every patient who can benefit from Soliris® (eculizumab) will
have access to Soliris. Since Soliris has become available, the vast majority of
patients for whom Soliris has been prescribed have gained access to the drug rapidly
and efficiently.
As part of its commitment to the PNH community in the United States, Alexion offers
the OneSource™ Treatment
Support Program, a personalized service for patients and their health care
providers. Each patient who enrolls in OneSource is assigned a specific Alexion Nurse Case Manager who supports the patient
immediately and over time, providing a broad range of services from disease education
to coordinating care between the physician's office and the insurer and assistance
with searches for alternative payment or funding options.
All Alexion Nurse Case Managers are registered nurses who have extensive experience
caring for patients and working in the health insurance industry. The OneSource
Treatment Support Program has helped many patients with PNH understand their treatment
options and make the most of their treatment plan. Patients and caregivers are encouraged
to call whether they are being treated with Soliris or not.
For patients whose insurance is not adequate, our Alexion Nurse Case Managers can
help to identify alternative coverage or funding. In addition, the National Organization
for Rare Disorders (NORD) has established the PNH Fund to assist underinsured patients.
Finally, our Alexion Nurse Case Managers will make referrals to the COMPLEMENT Foundation
for patients who do not have insurance, access to insurance, or any other means
for obtaining Soliris.
Alexion's commitment to access is for patients worldwide. The company works closely
with physicians, patients, and health authorities around the world to facilitate
access to Soliris.